Precision Health and PGx Podcast

National Adverse Drug Event Awareness Day Featuring The Right Drug Dose Act | PGX For Pharmacists

In recognition of National Adverse Drug Event Awareness Day, March 24, 2022, Dr. Becky Winslow, CEO of inGENEious RX Precision Medicine Consultants, and Dr. Behnaz Sarrami, PGx Medical Science Liaison of Missouri Pharmacogenomics Consulting, teamed up to cohost a special live episode of the PGx for Pharmacists Podcast. In this episode, Dr. Winslow and Dr. Sarrami interview Ms. Kristine Ashcraft, STRIPE Steering Committee member; former CEO and founder of YouScript; director of medical affairs at Invitae; a BIS Research recognized top 25 leading voice in precision medicine; and author of multiple publications on both the clinical and economic benefits of PGx testing, and Ms. Rachel Brummert, Special Government Employee (SGE) at the U.S. Food and Drug Administration; contributor at Drugwatch and Medshadow Foundation; and nationally recognized patient safety advocate who has turned the pain she suffered from an adverse drug event into her purpose. Topics discussed in this episode include: The financial and clinical costs resulting from adverse drug events' (ADEs) morbidity and mortality. Pharmacogenomic testing as a tool to mitigate ADEs. The Right Drug Dose Now Act which was recently introduced by Representatives Swalwell and Emmer and whose intent is to update the Department of Health and Human Services’ National Action Plan for Adverse Drug Event Prevention to include funding for pharmacogenomics testing advocacy. 

Clinical Decision Support Software: A Key Tool for Optimizing Population Health Level Pharmacogenomics Programs | PGx For Pharmacist

Episode Description:
On this episode, Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences, and I discuss the importance of population health level pharmacogenomics versus one time pharmacogenomics tests and how clinical decision support software that integrates pharmacogenomics data into patients’ medication therapy management is a key tool to optimize population health level pharmacogenomics programs.
References:
1. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program https://www.mdpi.com/2075-4426/12/3/421
2. Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report https://www.cureus.com/articles/81096-idiopathic-symptoms-resolved-by-pharmacogenomics-enriched-comprehensive-medication-management-a-case-report
3. Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry https://www.coriell.com/resources/consequences-of-cyp2d6-copy-number-variation-for-pharmacogenomics-in-psychiatry/
4. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978656/
5. ASP Establishes March 24th as National Adverse Drug Event Awareness Day https://www.stopadr.org/blog/asp-establishes-march-24-as-national-adverse-drug-event-awareness-day-launches-awareness-campaign
Guest’s Bio:
Jeffrey A. Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences (CLS), an international leader in precision medicine. Leveraging extensive experience in genetics and pharmacology, he is a leading expert in the rapidly evolving field of pharmacogenomics (PGx), the study of how an individual’s DNA impacts his or her response to medication. Most importantly, Dr. Shaman plays a critical role in bridging the gap between genetic science and clinical application. This includes translating decades of cutting-edge genetic research into actionable insights on the safest and most effective medications for individuals based on their unique DNA and dozens of other factors.
Driven to advance public health, Dr. Shaman is focused on enabling the delivery of personalized medicine at scale and empowering the most precise medical care worldwide. He consults with large employers, public and private payer organizations, healthcare systems, academic institutions, and laboratories around the globe, advising them on how to eliminate trial-and-error prescribing, improve population health, and control rising healthcare costs
Dr. Shaman is dedicated to setting the industry standard for PGx and pioneering new advancements in the field. Along with his team, he actively researches and presents findings in top peer-reviewed journals and at leading industry events. He is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, Personalized Medicine Coalition (PMC), Pharmacogenomics Global Research Network (PGRN), and other organizations.
Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Pharmacogenomics Changed My Life: A Patient’s Story, Kristen Ruth Davis | PGX For Pharmacists

Thanks for joining us today as our host, Dr. Jamie Wilkey talks with a patient, Kristen, who strongly feels that PGx testing saved her life. 
Join us for a patient’s side of the story today!
You may reach Kristen at her website: https://www.imnotcrazyproject.org/ her Facebook page: https://www.facebook.com/imnotcrazyproject or on LinkedIn: https://www.linkedin.com/in/kristen-ruth-davis-5540142a/
You may reach Jamie at her website: drjamiewilkey.com or on her LinkedIn page: https://www.linkedin.com/in/dr-jamie-wilkey/
*This episode discusses mental health and suicidal ideation. While it is not discussed in great detail, if you are having thoughts of ending your own life we strongly encourage you to push pause and call the National Suicide Prevention Hotline right away at 800-273-8255*
References:
IQVIA Institute for Human Data Science. Medicine Use and Spending in the U.S. https://www.iqvia.com/insights/the-iqvia-institute/reports/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023 Published May 2019. Accessed June 10, 2020.
Spear BB, Heath-Chiozzi M, Hu J. Clinical application of pharmacogenetics. Trends Mol. Med. 2001; 7, 201–204.
Table of Pharmacogenomic Biomarkers in Drug Labeling. U.S. Food and Drug Administration website.: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labelinghttps://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm Accessed June 10, 2020.
Preventable Adverse Drug Reactions: A Focus on Drug Interactions. U.S. Food and Drug Administration website. www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm110632.htm. Accessed June 10, 2020.
Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014; 95(4):423‐431.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Patient Impact of Limited Provider PGX Knowledge | PGX For Pharmacists

According to the American Academy of Family Physicians, there are more than 50 Cytochrome P450 enzymes but there are just 6 of them that metabolize about 90% of the drugs. One of the most significant ones is the CYP2D6. In an article on healio written by Dr. Jai Patel, he talks about CYP2D6 metabolizing many of the SSRIs, SNRIs and TCAs that are the treatment options for depression. The clearance of TCA’s for example is 50-67% lowered in CYP2D6 poor metabolizers compared to normal. www.aafp.org/afp/2007/0801/p391.html  Pharmacogenetic testing may improve outcomes for patients with depression (healio.com) Kristine Ashcraft is a molecular biologist by training and is the former CEO and founder of YouScript which was recently acquired by Invitae. She has worked in pharmacogenomics space since 2000 and was recently named one of the 25 leading voices in precision medicine. Kristine has authored multiple publications on both the clinical and economic benefits of PGx testing. She serves on the Steering Committee of STRIPE which is the FDA collaborative community for PGx. She has been interviewed by numerous media including the New York Times, the Wall Street Journal, and NBC Nightly News and has spoken at American Society of Human Genetics, and numerous precision medicine conferences and now speaking at one of the top 20 genomics podcast in the globe, PGx for Pharmacist Podcast. 

Pharmacists as Pharmacogenomic Counselors | PGX for Pharmacists

On this episode, Dr. Gillian Bell, a Doctor of Clinical Pharmacy, shares her path from pharmacy school to her non-traditional PharmD job as Pharmacogenomics Lead, Genome Medical.  On This Episode We Discuss:  • Gillian’s education (Brief)  • Gillian’s PharmD work experience prior to PGx (Brief) Residency  • Gillian’s PGx work experience prior to Genome Medical (Brief) Mission Hospital  • Brief description of Genome Medical, its mission, its services, its clients  • Gillian’s roles and responsibilities as the Pharmacogenomics Lead at Genome Medical  • What does a typical day at Genome Medical look like for its pharmacists? How do the pharmacists interact with the genetic counselors?  • “Genetic Counseling” or “PGx Inclusive Medication Therapy Management’ do the pharmacists provide one or the other or both? Neither? To whom are the services provided? Providers and/or to patients?  • Gillian’s advice to pharmacists who want to pursue a career in PGx  

Pharmacogenomics and Provider Status with Scott Knoer | PGX for Pharmacists

According to the National Community Pharmacists Association (NCPA), community pharmacists are highly accessible health care professionals and 95% of Americans live within just 5 miles of a pharmacy. (https://ncpa.org/provider-status) And what APhA or American Pharmacist Association, the largest association of pharmacists in the US is doing is laser focusing on getting provider status for pharmacists. So why is that important when it comes to PGx as this is a PGx podcast? Pharmacists can order the PGx test when they see fit for their patients without the need of a clinician to sign that form.  Scott Knoer, MS, PharmD, FASHP, became the 13th Executive Vice President and Chief Executive Officer of the American Pharmacists Association in June 2020, after serving for nine years as the Chief Pharmacy Officer at the Cleveland Clinic. Dr. Knoer is a passionate advocate for patients and the profession of pharmacy. He has successfully lobbied boards of pharmacy in Ohio and Minnesota to allow the advancement of pharmacy practice, and he has led initiatives that changed Ohio and federal law related to the elevation of pharmacy practice and reducing the impact of drug shortages. He received his BA in psychology from Creighton University and his PharmD from the University of Nebraska. 

Show Them the Money | PGX for Pharmacists

Pharmacogenomics Market Access and Reimbursement Series Episode Description:   Most of us understand that the reimbursement for pharmacogenomics tests has been one barrier amongst many barriers to pharmacogenomics’ wide-scale clinical adoption. Finding myself highly frustrated with the slow clinical uptake by PGx test ordering by healthcare providers back in 2017, I brainstormed about which payers were the most vested in improving patients’ medication outcomes and who would therefore more likely to listen to my pitch about PGX decreasing adverse drug events and increasing therapeutic medication outcomes. As a consultant to self-insured employers who were seeking to lower their employees’ drug spend, I found a warm and receptive audience for pharmacogenomics. It was through my relationships with self-insured employers that I met today’s guest. Again, fate intervened, and today’s guest reached out to me via LinkedIn. She had been following my pharmacogenomics posts and liking what she had seen she introduced me to a group of pharmacists in Kentucky who were integrating PGx into their PBM via comprehensive medication management.  Special Guest Jane Cheshire Gilbert, CPA Jane Cheshire Gilbert, CPA Director of Retiree Health Care for the Teachers’ Retirement System of the State of Kentucky Jane has served TRS retirees since April 2002. She manages two retiree health plans covering 48,000 retirees. She also serves as a leader in the areas of health insurance cost containment, project management, risk management and federal health care solutions. Gilbert served in management and directorship positions for a Louisville, Kentucky law firm and a cost containment company, The Rawlings Company, from 1989 through 2002. Prior to that, she worked as an accountant for a national CPA firm. Gilbert earned a bachelor’s degree in accounting from Bellarmine University in Louisville, Kentucky and is a certified public accountant and a certified government benefits administrator. She has served on the board of the State and Local Government Benefits Association and is a member of the Public Sector Healthcare Roundtable. 

Molecular Pharmacogenomics: An Australian Perspective | PGX for Pharmacists

Today’s episode is the 3rd episode in my PGx for Pharmacists Podcast series entitled, “The State of the PGx Industry: Pharmacogenomics Science and Research". I am super honored that, yet another one of my pharmacogenomics science expert colleagues is joining me on the podcast to provide my audience with high quality, evidence-based pharmacogenomics content. Today’s guest just so happens to be joining me from across the world! Like many of my guests, today’s guest started his pharmacist career in what we might define as a traditional pharmacist career path and then he transitioned his career to now create and research pharmacogenomic variant cell lines in the lab. His research will eventually be translated into predictive clinical pharmacogenomics software. Featured guest: Zeyad Ibrahim MClinPharm BPS BCOP AdvPP Consultant Cancer Pharmacist and Pharmacogeneticist 

Pharmacogenomics: A Primary for Clinicians | PGX for Pharmacists

Dr. Samit Shah serves as the Dean of the Regis University School of Pharmacy. Dr. Shah also served as the Assistant Dean and Department Chair of Biopharmaceutical Sciences at KGI SPHS. Dr. Shah earned a BS in pharmacy from North Gujarat University, a PhD in pharmaceutical sciences from the University of Missouri-Kansas City (UMKC), and an MBA from South University. He received post-doctoral training at the Massachusetts Institute of Technology (MIT). Dr. Lam received her Doctor of Pharmacy degree from the University of Southern California (USC). She completed a two-year fellowship at USC School of Pharmacy in HIV pharmacotherapy and translational research. She is credentialed by the American Academy of HIV Medicine. She is currently an Associate Professor at Chapman University School of Pharmacy. Dr. Lam currently practices in a multidisciplinary medical team treating general medicine, HIV and HIV/HCV coinfected patients with the AltaMed Medical Group in Santa Ana. Dr. Lam has also authored several book chapters and journal articles on these topics. Together with Dr. Mary Gutierrez they have written the book called Pharmacogenomics: A primary for clinicians. Now available on Amazon.

What the Cannabis Does this Have to do with PGx? | PGX for Pharmacists

On this episode of the PGx for Pharmacists Podcast, Dr. Codi Peterson, a Doctor of Clinical Pharmacy and pediatric pharmacist, and discusses what was once a taboo subject for pharmacists and that is cannabis. We will explore how pharmacy has and hasn’t progressed in its acceptance of cannabis over the years, what roles Codi plays in the cannabis industry, how he has often had to make clinical decisions with limited pediatric data and how he applies the same logic to evaluate cannabinoid- based therapies. As well, we will discuss the pharmacogenomics, pharmacokinetics, and pharmacodynamics of cannabis. On This Episode We Discuss: · Codi’s education (Brief) · Codi’s non-cannabis PharmD work experience (Brief) · What sparked Codi’s interest in cannabis? · Cannabis’ mechanism of action and possible reasons why it isn’t yet a standard medication · Codi’s PGx cannabis work experience · PGx of Cannabis Guest and Contact Info: Codi Peterson, PharmD, RPh pedrphphx@gmail.com